Table 9.

Correlation of clinical–pathological and molecular characteristics with the FPd molecular scores for aggressiveness

Parameter	No. of patients (n)	FPd score1 (Spearman rs)	P
Age	39	0.167	0.311
Prebiopsy PSA	39	0.536	<0.0001
Prostate size	39	−0.467	0.003
PSA density	39	0.845	<0.0001
Gleason score	39	0.659	<0.001
No. of cores with cancer	39	0.423	0.007
Max. % cancer inv. in any core	39	0.564	<0.0001
Urine PSA	39	0.185	0.258
Urine PCA3	39	0.083	0.616
Urine ERG(5-6)	39	0.227	0.164

PSA, prostate-specific antigen.

¹Spearman's rank correlation test to measure correlation of the FPd score with each parameter.